JTFM, Yes I know he was not talking about "potential" peak market for Corti, he was comparing it to past peak patient counts in 2017. I agree you, with all the work they are doing to educate and re-educate the payers, doctors and patients about ACTH, hopefully they can blow past that 2017 peak, in a few years.
Nikhil should be a golfer he is such a sandbagger! The 24 guidance numbers just seemed way to low to me. I had to re-read the EC transcript. He is calling for 520-542M in revenue for 2024, with Corti Rev of 170-180M (not including any new indications ie gouty arthritis), Generics revenue to grow high single to low double digits growth.
In 2023 their Rev was 486.8M, Corti Rev. 112M, Generics 269.4M, Branded products, royalties and other Rev. 105.3M. Using Nikhil's Conservative guidance,
Corti will be up 58M to 68M, Generics should be up 24.2M--32.3M using 9% low and 12% high side of guidance. They didn't give guidance on Branded products and royalties, assume this stays the same at 105.3M YoY. If that's the case, that brings us to 569-587M for 2024 revenue, that also doesn't include any new generics or new Corti indications. So unless the Branded drug and Royalties and other has a major crash this year, we should see a least a couple more Beat and Raise ER's coming this year! Btw how is the sale of the Oakville plant, I think 13M USD in Q1, accounted for?
Bullish
News 
Market Data 
Discover 
AI
